Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14133MR)

This product GTTS-WQ14133MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Atherosclerosis&Acute coronary syndrome (ACS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14133MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8623MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ11387MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ13247MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ5383MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ9711MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ6351MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ86MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 1121B
GTTS-WQ8232MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HLX-06
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW